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MAP kinase phosphatases (MKPs) catalyze dephosphorylation of activated MAP kinase (MAPK) molecules and deactivate them. Therefore,
MKPs play an important role in determining the magnitude and duration of MAPK activities. MKPs constitute a structurally distinct family of
dual-specificity phosphatases. The MKP family members share the sequence homology and the preference for MAPK molecules, but they are
different in substrate specificity among MAPK molecules, tissue distribution, subcellular localization and inducibility by extracellular stimuli. Our
understanding of their protein structure, substrate recognition mechanisms, and regulatory mechanisms of the enzymatic activity has greatly
increased over the past few years. Furthermore, although there are a number of MKPs, that have similar substrate specificities, non-redundant roles
of MKPs have begun to be identified. Here we focus on recent findings regarding regulation and function of the MKP family members as
physiological regulators of MAPK signaling.
© 2006 Elsevier B.V. All rights reserved.Keywords: MAP kinase; MAP kinase phosphatase; Dual-specificity phosphatase1. Introduction
The MAP kinase (MAPK) signaling pathways are evolu-
tionally highly conserved, and involved in diverse cellular
functions, including cell proliferation, differentiation and stress
responses. A wide variety of extracellular stimuli, such as
growth factors and environmental stresses, induce sequential
phosphorylation and activation of three protein kinases, MAP
kinase kinase kinase (MAPKKK), MAP kinase kinase
(MAPKK) and MAPK. MAPK is a serine/threonine kinase
activated by MAPKK via phosphorylation on both threonine
and tyrosine residues within the conserved TXY sequence. The
MAPK family consists of four members, ERK1/2 (also known
as classical MAPK), JNK/SAPK, p38 and ERK5/BMK1. Each
molecule is activated in distinct pathways and transmits signals
either independently or coordinately [1–6]. One of interesting
features of MAPK signaling is that the activation of a single
MAPK pathway is able to transduce multiple extracellular
stimuli to their specific cellular responses. Accumulating⁎ Corresponding author. Tel.: +81 75 753 4230; fax: +81 75 753 4235.
E-mail address: L50174@sakura.kudpc.kyoto-u.ac.jp (E. Nishida).
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doi:10.1016/j.bbamcr.2006.12.002evidence has demonstrated that differences in the duration and
magnitude of MAPK activities regulate signaling specificity
[7–9]. In other words, fine tuning of MAPK activity is
important in determining signaling outcomes. Thus, inactiva-
tion of MAPK plays a pivotal role in various physiological
processes.
Activated MAPKs are inactivated through dephosphoryla-
tion of threonine and/or tyrosine residues within the activation
loop. The dephosphorylation could be achieved by serine/
threonine phosphatases, tyrosine phosphatases and dual-speci-
ficity phosphatases. The serine/threonine phosphatases which
dephosphorylate MAPKs include PP2A and PP2C [10]. The
tyrosine phosphatases which dephosphorylate MAPKs include
three MAPK-specific tyrosine phosphatases, STEP, HePTP and
PTP-SL [11,12]. These serine/threonine phosphatases and
tyrosine phosphatases have been covered in recent reviews
[13–17]. Here we review the dual-specificity MAP kinase
phosphatases (MKPs).
2. Overview of the MKP family
MKPs belong to a family of dual-specificity phosphatases
and specifically dephosphorylate both threonine and tyrosine
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composed of two domains, the MAPK-binding (MKB) do-
main in the N-terminal half and the dual-specificity phospha-
tase (DSP) domain in the C-terminal half. The C-terminal DSP
domain is homologous to the prototypic dual specificity
protein phosphatase VH-1 of vaccinia virus, and the N-
terminal MKB domain, which is homologous to the rhodanese
family of sulphotransferases, contains two regions of sequence
homology with the catalytic domain of the cdc25 phosphatase
[18]. The DSP domains of all MKPs share strong homology
with each other. Because the DSP domain alone does not
show strict selectivity towards the members of MAPKs
[19,20], the N-terminal MKB domain plays a major role in
regulating their enzymatic specificity through docking inter-
action with MAPKs. The MKB domain contains a cluster of
positively charged amino acids, which play a role in
determining binding specificity of MKPs towards MAPKs
[21,22]. In addition, a cluster of hydrophobic amino acids and
another cluster of positively charged amino acids are required
for the specific interaction of MKPs with MAPKs [23] (Fig.
1A). It has been shown that several MKPs are catalytically
activated by substrate binding to its MKB domain [24–28].
Binding of phosphorylated MAPK to the MKB domain alters
the structure of the DUSP domain. This conformational
change, along with the interaction of the catalytic domain with
MAPK, greatly enhances the catalytic activity of MKPs
[29,30] (Fig. 1B). The details of structure, substrate binding
and catalytic activation of MKPs are reviewed in a number of
recent reviews [14,15,17,31,32].Fig. 1. Interaction of MKPs with MAPKs. (A) The docking interaction between MAP
divided into three modules, binds to the corresponding sites in MAPKs. (B) Activation
is inactive without its substrate. Binding of activated MAPKs to the MKB domain ind
its catalytic activity.3. Classification of MKPs
MKPs are highly specific for MAPKs but differ in the
substrate specificity among the MAPK family members, tissue
distribution, subcellular localization and inducibility by extra-
cellular stimuli. Based on the sequence similarity, protein
structure, substrate specificity and subcellular localization, the
MKP family can be divided into three groups [31,32]; Type I,
Type II, and Type III (Fig. 2, Table 1).
Type I MKP is a group of MKPs which localize in the
nuclear compartment and are induced by many of stimuli that
activate MAPKs. For this reason, it has been suggested that
these MKPs play an important role in the feedback control of
MAPK signaling in the nucleus. Thus, Type I MKP is an
inducible nuclear MKP. Type I MKPs include MKP-1, MKP-2,
PAC1, and hVH3. MKPs in this group consist of 300 to 400
amino acid residues, and contain a nuclear localization signal
(NLS) sequence in their N-terminus [33].
Those MKPs that have a nuclear export signal (NES) and
localize in the cytoplasm are classified as Type II MKP. Type II
MKP includes MKP-3, MKP-X and MKP-4. Type II MKP is
also called the Pyst subfamily of dual-specificity phosphatases.
MKP-3, MKP-X and MKP-4 are thus also called Pyst-1, 2 and
3, respectively. MKPs in this group show restricted tissue
distribution.
MKP-5, MKP-7 and M3/6 constitute the group of Type III
MKP, and selectively dephosphorylate JNK and p38 but not
ERK1/2. They have an extended region either in the N-
terminus (MKP-5) or in the C-terminus (MKP-7 and M3/6) inKs and MKPs. The docking surface in the MKB domain of MKPs, which can be
of MKPs by MAPKs. The dual-specificity phosphatase (DSP) domain in MKPs
uces conformational changes in the DUSP domain, which causes the increase of
Fig. 2. Classification and domain structure of the MKP family. Domain structures of the three subgroups of MKPs are shown. VHR is an atypical “MKP”. In addition to
the MAPK binding (MKB) domain and dual-specificity phosphatase (DUSP) domain, nuclear localization signal (NLS), nuclear export signal (NES), and PEST
sequences are indicated.
Table 1
General features of MKPs
Type Name Other name DUSP No. MAPK specificity Subcellular
localization
I MKP-1 CL100,
3CH134,
erp, hVH1
DUSP1 p38, JNK>ERK1/2 Nuclear
PAC1 DUSP2 ERK1/2>p38 Nuclear
MKP-2 hVH2,
TYP2,
STY8
DUSP4 ERK1/2, JNK Nuclear
hVH3 B23 DUSP5 ERK1/2 Nuclear
II MKP-3 Pyst1,
rVH6
DUSP6 ERK1/2 ERK5 Cytoplasmic
MKP-X Pyst2,
B59
DUSP7 ERK1/2>JNK Cytoplasmic
MKP-4 Pyst3 DUSP9 ERL1/2, p38 Cytoplasmic
III MKP-5 DUSP10 JNK, p38 Nuclear/
Cytoplasmic
MKP-7 MKP-M DUSP16 JNK, p38 Nuclear/
Cytoplasmic
M3/6 hVH5,
HB5
DUSP8 JNK, p38 Nuclear/
Cytoplasmic
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of this region of MKP-5 is unclear, the C-terminal region of
MKP-7 and M3/6 contains NLS, NES and the PEST se-
quence, which is frequently found in rapidly degraded
proteins [34]. Removal of the PEST sequence from these
proteins results in their stabilization [35], suggesting a role for
the sequence in rapid turnover. Although Type III MKPs are
too large to enter the nucleus by passive diffusion, they
localize both in the cytoplasm and nucleus.
There are atypical “MKPs” that consist of only a catalytic
domain with no recognized targeting or docking sequence.
These phosphatases consist of the DUSP domain alone and
small (approximately 200 amino acids). Some of these
phosphatases are able to dephosphorylate MAPKs [36–39].
Although biochemical and structural properties of MKPs
have been studied extensively over the past decade, the
physiological function of MKPs, including substrate specificity
in vivo, has not been fully defined. Here we review the
regulation and function of MKPs focusing on recent studies that
used knockout mice.
4. Type I MKP
4.1. MKP-1
MKP-1, the firstly discovered MKP, was identified as an
immediate early gene that is induced rapidly after exposure to
growth factors, heat shock and oxidative stress [40–42]. It was
reported that in fibroblasts, the time course of induction of
MKP-1 after stimulation was similar to the time course of
ERK1/2 inactivation. Purified recombinant MKP-1 depho-
sphorylates ERK1/2 in vitro, and expression of MKP-1 in cells
blocks activation of ERK1/2 [43–45]. Despite these earlystudies, MKP-1 seems to act on JNK and p38 rather than ERK1/
2 under physiological conditions, because it has been shown
that MKP-1 more effectively inactivates JNK and p38 than
ERK1/2 in vitro and the ERK1/2 activity is not affected in the
MKP-1 deficient fibroblasts [46–48]. The catalytic activity of
MKP-1 is enhanced by its binding to substrates through the
MKB domain [49].
MKP-1 expression is induced by growth factors, heat shock
and oxidative stress through activation of ERK1/2. Moreover,
ERK1/2 phosphorylates and stabilizes MKP-1 protein [50].
More recently, it was reported that activation of p38 also
Fig. 3. Roles of MKP-1 and MKP-5 in immunity. In macrophages, LPS binding
to Toll-like receptor (TLR) activates both the p38 pathway and the JNK
pathway, which induce the expression of inflammatory cytokines. LPS signaling
also induces both MKP-1 and MKP-5 expression, and MKP-1 and MKP-5
specifically downregulate p38 and JNK, respectively.
1230 K. Kondoh, E. Nishida / Biochimica et Biophysica Acta 1773 (2007) 1227–1237stabilizes MKP-1 through MAPKAP kinase 2 [51]. Therefore,
MKP-1 is involved in a negative feedback loop of MAPK
signaling, and its expression level seems to be modulated at
multiple stages.
MKP-1 is used as a mediator of a cross-talk between the
MAPK pathway and the other signaling pathways. MKP-1 is a
transcriptional target of the tumor suppressor p53 [52]. TGF-β
signaling and retinoid acid signaling upregulate MKP-1
expression [53,54]. Moreover, while PKCζ induces MKP-1
expression in response to hypoxia [55], PKCδ triggers MKP-1
degradation in glutamate-induced cell death [56]. In addition,
MKP-1 is induced by several hormones, such as glucocorti-
coids, endocannabinoid and parathyroid [57–59].
MKP-1 deficient mice appear normal and fertile, and
fibroblasts derived from mice lacking MKP-1 have unaltered
ERK1/2 activation, cell growth and c-fos expression in response
to serum [47]. Therefore, the physiological role of MKP-1 was
unknown. However, recent studies provided evidence for
essential roles of MKP-1 in the regulation of p38 and JNK.
First, primary mouse embryonic fibroblasts (MEFs) derived
from mice lacking MKP-1 exhibit hyperactivation of p38 and
JNK in response to serum, osmotic stress and anisomycin [60].
In addition, MKP-1 is shown to be required for attenuation of
cAMP-induced p38 activation and CREB responsiveness.
Interestingly, MKP-1-deficient MEFs exhibit reduced cell
growth as a result of enhanced sensitivity to cell death and
stress-induced apoptosis. Therefore, MKP-1 plays a critical role
in the negative regulation of p38 and JNK in response to stress
[60]. In a more recent study, hyperactivation of ERK1/2, p38,
and JNK is seen in insulin-response tissues in MKP-1-deficient
mice [61]. MKP-1-deficient mice show resistance to diet-
induced obesity due to enhanced energy expenditure, which is
independent of glucose homeostasis. Moreover, the activities of
these three MAPKs are increased in the nucleus, but not in the
cytoplasm. Thus, nuclear regulation of MAPKs by MKP-1 is
essential for the management of metabolic homeostasis [61].
Macrophages from mice lacking MKP-1 also show increased
JNK and p38 activities in response to lipopolysaccharide (LPS)
[62]. Moreover, MKP-1-deficient macrophages are highly
sensitive to endotoxic shock and produce both pro- and anti-
inflammatory cytokines, including TNF, IL-6 and IL-10, more
robustly and rapidly than wild-type macrophages [63–66]. The
overproduction of these cytokines is dependent on p38 activity
[63]. Therefore, MKP-1 plays a role in regulating inflammation
during innate immune response by regulating p38 activity (see
Fig. 3).
4.2. PAC-1
PAC-1 was originally identified as a mitogen-inducible
gene in human T cells [67]. It is highly induced in T cells and
B cells upon activation [68]. Activation of the ERK1/2 path-
way induces PAC-1 expression [67]. PAC-1 specifically
dephosphorylates ERK1/2 and p38 in vitro [46,69]. Notably,
while the interaction of the PAC-1 MKB domain with ERK1/2
increases PAC-1 catalytic activity, its interaction with p38 does
not [28].Recent studies have revealed in vivo function of PAC-1. It
has been shown that transcription of PAC-1 is activated by
p53 through a palindromic site in the PAC-1 promoter during
apoptosis [70]. Serum withdrawal and oxidative stress induce
p53-dependent apoptosis and PAC-1 transcription. PAC-1
overexpression enhances sensitivity to apoptosis and sup-
presses tumor formation. Inhibition of PAC-1 expression by
RNA interference inhibits p53-mediated apoptosis. Therefore,
it is likely that PAC-1 is required for p53-mediated apoptosis.
In this case, ERK1/2 activity is decreased by p53 activation,
suggesting that PAC-1 specifically dephosphorylates ERK1/2
in vivo. As p38 activity is not investigated in the study, it is
unclear whether PAC-1 dephosphorylates p38 in vivo. PAC-1
is identified as one of the most highly induced transcripts in
activated immune effector cells as well as one of the most
abundant and regulated MKPs in many activated leukocytes
[71]. Thus, PAC-1 may serve as a chief regulator of MAPK
activities in immunity, especially in immune effector cells
associated with inflammatory reaction. Detailed analyses of
recently generated PAC-1 knockout mice have identified novel
function of PAC-1 in immune system [71]. PAC-1 null mice
develop and age normally, and show no abnormalities in basic
immune features. On the other hand, they show considerably
reduced inflammatory responses in the autoimmune model of
rheumatoid arthritis, in which disease pathogenesis is
dependent on effector leukocytes. Therefore, although PAC-1
has no obvious function in immune cell development, it has a
critical positive function in promoting inflammatory res-
ponses. Consequently, LPS-stimulated PAC-1 null macro-
phages produce fewer pro-inflammatory mediators, cytokines
and inflammatory chemokines when compared with LPS-
1231K. Kondoh, E. Nishida / Biochimica et Biophysica Acta 1773 (2007) 1227–1237stimulated normal macrophages. Notably, PAC-1 deficiency
leads to increased JNK activity but unexpected impairment of
ERK1/2 and p38 activities. This is surprising because it has
been shown that PAC-1 dephosphorylates ERK1/2 and p38,
but not JNK [28,46,69]. Pharmacological inhibition of JNK
activity can rescue the reduced phosphorylation of ERK1/2
[71], suggesting that loss of PAC-1 may decrease ERK1/2
activity by upregulating JNK activity. Therefore, it is likely
that there is a cross-talk between ERK1/2 and JNK. In
addition, how PAC-1 targets JNK in immune system should be
examined.
4.3. MKP-2
MKP-2 is the other member of type I MKP [72,73]. It has
been shown that MKP-2 is induced by growth factors [73,74],
gonadotropin-releasing hormone (GnRH) [75], retinoic acid
[54] and the oncogene v-jun [76]. Activation of the ERK1/2
pathway induces MKP-2 expression [74]. Moreover, cellular
senescence increases MKP-2 protein by blocking its degrada-
tion [77]. MKP-2 specifically dephosphorylates ERK1/2 and
JNK in vitro [46], and the interaction of MKP-2 with ERK1/2
and JNK enhances its catalytic activity [25]. However, the
substrate specificity of MKP-2 in vivo is still unclear. It has
been reported that MKP-2 dephosphorylates JNK, but not
ERK1/2 in UV-C or cisplatin treated cells [78]. In these cells,
while JNK translocates to the nucleus, ERK1/2 remains in the
cytoplasm. Therefore, MKP-2 may dephosphorylate nuclear
JNK, but not cytoplasmic ERK1/2. Recently, MKP2 is shown to
be a transcription target of p53 in mediating apoptosis [79].
MKP2 is induced by oxidative stress in a p53-dependent
manner.
4.4. hVH3
hVH3 is induced by heat shock and growth factors [80,81].
In peripheral blood T lymphocytes, IL-2, IL-7 and IL-15 induce
hVH3, and IL-2 induced ERK1/2 activation is inhibited by
hVH3 [82], suggesting a negative feedback role for hVH3 in IL-
2 signaling. Moreover, anti-CD3 stimulation of thymocytes
strikingly induces hVH3 [83]. Therefore, hVH3 might play an
important role in T cells. hVH3 interacts with and depho-
sphorylates ERK1/2 but not JNK or p38. It is possible that
hVH3 is a direct transcriptional target of the tumor suppressor
p53 [84].
A recent study has shown that hVH3 can regulate subcellular
localization of ERK1/2 [85]. Expression of hVH3 causes both
nuclear translocation and sequestration of ERK1/2. This nuclear
anchoring is ERK1/2 specific and requires both the functional
NLS in hVH3 and the interaction between the hVH3 MKB
domain and the ERK1/2 common docking (CD) domain.
Moreover, the catalytically inactive mutant of hVH3 can also
anchor ERK1/2 in the nucleus. Interestingly, the inactive hVH3-
anchored nuclear ERK1/2 is phosphorylated by MEK1/2 upon
stimulation and the activated ERK1/2 is able to activate its
nuclear target Elk-1. The results suggest that hVH3 functions as
a nuclear anchor for ERK1/2.5. Type II MKP
5.1. MKP-3
MKP-3 is specific to ERK1/2 and ERK5 [86–90]. To date,
MKP-3 is the only MKP that is shown to dephosphorylate
ERK5. ERK1/2 binding to the MKB domain of MKP-3
increases its phosphatase activity [19,24]. MKP-3, as well as
MKP-1, is phosphorylated by ERK1/2 and this phosphorylation
facilitates proteasomal degradation of MKP-3 [91]. As MKP-3
shuttles between the cytoplasm and the nucleus and is able to
anchor ERK1/2 in the cytoplasm, it has been suggested that
MKP-3 may play a role in determining cytoplasmic localization
of ERK1/2 [92].
Regulatory mechanisms of MKP-3 expression seem to be
cell type-dependent. While MKP-3 appears to be constitutively
expressed in some cell types, it is induced by some growth
factors, such as nerve growth factors and basic fibroblast growth
factors [86,93,94]. MKP-3 is expressed in insulin-responsive
tissues, and its expression in liver is markedly elevated in
insulin-resistant obese mice [95]. In developing mouse
embryos, MKP-3 mRNA is detected in presegmental paraxial
mesoderm, limb bud and branchial arch mesenchyme, mid-
brain/hindbrain isthmus and nasal, dental, hair and mammary
placodes [96]. As most of these have been characterized as sites
of FGF/FGFR signaling, MKP-3 seems to be involved in the
FGF/FGFR signaling pathway during early development.
During limb development, the apical ectodermal ridge (AER)-
derived FGF8 is a key factor, and its signal should be
transmitted to the underlying mesenchyme [97]. It has been
shown that MKP-3 is induced by FGF8 in chick, mouse and
zebrafish limb/fin buds [98]. While a high level of phosphory-
lated ERK1/2 is detected in the AER, MKP-3 expression and
Akt phosphorylation are reported to be detected only in the
mesenchyme [98]. Therefore, it is likely that induction of MKP-
3 expression by FGF8 is mediated through the PI3K pathway
(Fig. 4). The phosphorylation status of ERK1/2 in the
mesenchyme is controversial. While several studies reported
that phosphorylated ERK1/2 is detected in the mesenchyme
[99,100], another study failed to detect phosphorylated ERK1/2
[98]. However, mice lacking PDK1, an essential mediator of the
PI3K pathway, express MKP-3 in limb buds [100]. Thus it is
possible that the ERK1/2 pathway, as well as the PI3K pathway,
is involved in the mechanism of MKP-3 expression (Fig. 4).
While inhibition of MKP-3 expression induces apoptosis in the
mesenchyme, MKP-3 overexpression causes developmental
abnormalities, suggesting that MKP-3 plays a pivotal role in
limb development by setting an appropriate level of ERK1/2
activity [98]. In support of this notion, both gain- and loss-of-
function studies in the zebrafish embryo also have shown that
MKP-3 is required for controlling the extent of ERK1/2 activity
[101]. In addition, recent studies have revealed that expression
of MKP-3 is also regulated by FGF in chicken neural plate, in
mouse isthmic organizer during neural tube development and in
developing chick somite [102–104]. Interestingly, while
expression of MKP-3 is induced by FGF through the PI3K
pathway in limb and isthmic organizer [98,103], it is induced
Fig. 4. Role of MKP-3 in limb bud development. In apical ectodermal ridge
(AER), ERK1/2 is activated by FGF signaling. On the other hand, in
mesenchyme, FGF signaling induces MKP-3 expression through activation of
the PI3K-Akt and the ERK1/2 pathways. Then, ERK1/2 is inactivated by MKP-
3 in mesenchyme. This MKP-3 function is important for normal limb
development.
1232 K. Kondoh, E. Nishida / Biochimica et Biophysica Acta 1773 (2007) 1227–1237through the ERK1/2 pathway in neural plate and somite
[102,104]. Expression of MKP-3 is also reported to be regulated
by a maternal β-catenin signal and retinoic acid signaling
[101,105].
5.2. MKP-X
It has been shown that MKP-X is able to form a complex with
ERK1/2 and preferentially targets ERK1/2 protein as its substrate
in vitro [86]. In addition, MKP-X binds to and dephosphorylates
JNK in vitro [106]. Both MKP-X mRNA and protein are
expressed in bone marrow, peripheral leukocytes from acute
myeloid leukemia and several leukemia cells [107–109].
However, the biological function of MKP-X remains unclear.
5.3. MKP-4
MKP-4 specifically blocks activation of ERK1/2 when
expressed in cells [110] and dephosphorylates ERK1/2 and p38
in vitro [111]. MKP-4 shows a highly restricted tissue
distribution; it is expressed only in placenta, kidney, embryonic
liver, migrating muscles and insulin-response tissues [110,111].
MKP-4 is identified as a candidate gene involved in the
negative regulation of insulin signaling [112]. MKP-4 is
expressed in the insulin-response tissues and the expression
levels are up-regulated in obese, insulin-resistant rodent models.
Expression of MKP-4 inhibits insulin-induced adipogenesis inpreadipocytes and glucose uptake in adipocytes. It has also been
reported that MKP-4 attenuates p38 activity and inhibits
arsenite-induced glucose uptake in adipocytes [113]. Therefore,
these studies suggest that MKP-4 negatively regulates insulin
signaling via dephosphorylation of p38. The other physiological
function of MKP-4 is revealed by the MKP-4 knockout mice
study [114]. MKP-4 gene is on the X chromosome, and both
female heterozygous and male null mice die in utero. The
developmental defect is characterized by a failure to form a
functional labyrinth, and this is consistent with the high
expression of MKP-4 in the wild type placenta. When the
placental defect was rescued, male null embryos developed to
term, appeared normal and were fertile. Therefore, MKP-4 is
essential for the extracellular placenta development. Surpris-
ingly, loss of MKP-4 did not lead to significant changes in the
basal phosphorylation state of any MAPKs in placental tissues.
It is, however, possible that significant changes in MAPK
activities were occurring in restricted compartments and/or time
periods. Notably, the placental defects are caused also by the
loss of MEK1, a MAPKK of ERK1/2, and p38α [115,116],
suggesting that MKP-4 is involved in regulation of either or
both of the ERK1/2 and p38 pathways. As MKP-4 seems to
play a role in insulin signaling, it would be interesting to
examine the insulin-resistance of MKP-4 knockout mice.
6. Type III MKP
6.1. MKP-5
MKP-5 binds to and dephosphorylates JNK and p38, but not
ERK1/2 [20,117]. p38 is a preferred substrate. MKP-5 is
expressed in heart, lung, liver, kidney and skeletal muscle.
MKP-5 expression in cultured cells is elevated by stress stimuli.
MKP-5 is also identified as a gene that is induced by DNA
double-strand break in an ATM-dependent manner [118].
Recently, MKP-5 function in immune response has been
demonstrated [119]. MKP-5 expression is strongly induced
upon LPS treatment in macrophages, constitutive in naive
CD4+ T cells and downregulated after T-cell activation. Then
MKP-5 deficient mice were created to understand the role of
MKP-5 in regulating MAPK during immune response. Deletion
of MKP-5 does not cause any developmental defects, and
lymphoid and myeloid cells develop normally in the absence of
the MKP-5 gene, indicating that MKP-5 is not required for
development of the immune system. However, T cells lacking
MKP-5 exhibit markedly enhanced JNK activity but no
enhancement in p38 activity. Increased JNK activity is also
observed in MKP-5 deficient macrophages after LPS treatment.
Thus, MKP-5 may function to decrease JNK activity in immune
responses. MKP-5 null macrophages upon treatment with LPS
express increased levels of the pro-inflammatory cytokines, and
MKP-5 null T-cells are activated greater than wild type cells. In
addition, MKP-5 deficient antigen-presenting cells (APCs)
show enhanced T cell priming activity. These results suggest
that MKP-5 is a negative regulator of innate immunity (see Fig.
3). On the other hand, MKP-5 deficient T-cells show reduced
proliferation capability upon activation, suggesting that MKP-5
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analyses in MKP-5 deficient mice suggest that MKP-5 has a
principal function in both innate and adaptive immune responses
[119].
As MKP-1-deficient mice, as well as MKP-5 deficient mice,
show the immune defects (see above), it seems interesting to
examine the differences in their phenotypic features in detail.
While MKP-1-deficient macrophages exhibit enhanced p38
activity and overproduce pro- and anti-inflammatory cytokines,
MKP-5 deficient macrophages exhibit enhanced JNK activity
and overproduce pro-inflammatory cytokines (see Fig. 3).
Therefore, although both MKP-1 and MKP-5 dephosphorylate
both p38 and JNK in vitro, they may have different substrate
specificities in macrophages.
6.2. MKP-7
MKP-7, the biggest molecule in the MKP family, has a
unique long C-terminal region that contains both NLS and NES,
by which MKP-7 shuttles between the nucleus and the
cytoplasm [120,121]. MKP-7 binds to and dephosphorylates
JNK and p38 but not ERK1/2 [120,121]. MKP-7 expression is
induced by JNK activation [122] and by LPS stimulation in
macrophages [35]. It has been shown that MKP-7 binds to
ERK1/2 through its C-terminal region, which is phosphorylated
by ERK1/2 in response to several extracellular stimuli [123].
This phosphorylation of MKP-7 by ERK1/2 suppresses the
proteasomal degradation of MKP-7. As MKP-7 dephosphor-
ylates JNK and p38 but ERK1/2, it is possible that the ERK1/2
pathway inhibits JNK or p38 activity via MKP-7 stabilization.
JIP-1, a scaffold protein for the JNK pathway, binds to JNK,
MKK7 and MLKs, and facilitates activation of the JNK
pathway [124]. MKP-7 binds to JIP-1 through its C-terminal
region and inactivates JNK [125]. Moreover, MKP-7 also binds
to β-arrestin 2 via the same region that interacts with JIP-1
[126]. MKP-7 dephosphorylates JNK-3, which binds to β-
arrestin 2, upon activation of the JNK-pathway by ASK1
expression or the angiotensin receptor stimulation. The
physiological function of MKP-7 is to be elucidated.
6.3. M3/6
M3/6 (also called hVH-5) displays specificity towards
inactivation of JNK and p38 [89,127]. M3/6 has both NES
and NLS sequences in its C-terminal region, which is very
similar to that of MKP-7, and also shuttles between the
cytoplasm and the nucleus. Like MKP-7, M3/6 binds to JIP-1
[125]. M3/6 is expressed predominantly in the adult brain, heart,
and skeletal muscle [127]. M3/6 expression is induced in the
brain by cocaine and odor treatment, suggesting its role in the
brain [128,129]. Its expression and activity could also be
regulated by those stress stimuli, that usually upregulate JNK
activity. Oxidative stress decreases the expression of M3/6
[130]. M3/6 dissociates from JNK and appears in an insoluble
fraction after heat shock [131]. Moreover, while phorbol ester
induces JNK activation and increases the steady-state level of
M3/6, to form a feedback loop [132], anisomycin and arseniteinactivate M3/6 activity [133]. It has also been suggested that
M3/6 is phosphorylated in response to stress stimulation [132].
7. Atypical “MKP”
7.1. VHR
As VHR (Vaccinia H1-related) is the firstly identified dual
specificity phosphatase in mammals [134], the catalytic domain
of VHR has been the subject of detailed biochemical and
structural analyses. VHR inactivates ERK1/2 and JNK in vivo
and in vitro [36,37,135]. VHR is not acutely induced in
response to MAPKs activation. Most recently, however, it has
been reported that ERK1/2 positively regulates VHR phospha-
tase activity by inducing VRK3, a member of the Vaccinia-
related kinase (VRK) family [136]. VRK3 enhances VHR
activity by a mechanism independent of its kinase activity
through its direct binding to VHR. Interestingly, ERK1/2
activation induces VRK3 expression. Therefore, activation of
the ERK1/2 pathway induces VRK3 and enhances VHR
activity, forming a feedback loop [136]. VHR is expressed in
lymphoid and hematopoietic cells and is constitutively
expressed in T cells, and negatively regulates T-cell receptor
induced ERK1/2 and JNK activation [36]. Moreover, VHR is
phosphorylated by ZAP-70, a protein tyrosine kinase which is
of importance in T and NK cell signaling, and this phosphor-
ylation is required for VHR to inhibit the ERK1/2 pathway in
response to T-cell receptor activation [137]. In addition to its
function in immune system, a recent study has reported that
VHR plays an important role in cell cycle regulation [138].
VHR is barely detectable in cells in G1 phase, but then
gradually increased during progression of the cells through S
phase and is most abundant in mitotic cells. Inhibition of VHR
expression by RNA interference arrests cells in the G1/S and
G2/M transitions and causes the initial sign of senescence. In
DNA microarray analysis, about 200 genes are downregulated
and about 100 genes upregulated by VHR RNA interference. In
agreement with the cell cycle arrest and senescence seen in cells
lacking VHR, the most upregulated gene is p21, a CDK
inhibitor, whereas the downregulated genes include cell cycle
regulators, such as CDK2, CDC2, cyclinA2 and E2, general
transcription factors, RNA polymerase I and II, DNA replica-
tion machinery and DNA repair proteins. Loss of VHR also
causes several fold increase of serum-induced activation of
ERK1/2 and JNK. Furthermore, VHR deletion-induced cell-
cycle arrest is dependent on hyperphosphorylation of ERK1/2
and JNK. Therefore, VHR is required for cell-cycle progression
and modulates ERK1/2 and JNK activation in a cell-cycle phase
dependent manner [138].
8. Other lowmolecular weight dual-specificity phosphatases
MKP-6, which is not a typical MKP, is composed of its DSP
domain alone, like VHR. MKP-6 can dephosphorylate ERK1/2
and JNK in vitro [139]. MKP-6 interacts with CD28 and is
induced by TCR and CD28 co-stimulation in T cells, suggesting
that MKP-6 functions as a negative-feedback regulator of CD28
Table 2
Low molecular weight dual-specificity phosphatases that dephosphorylate
MAPKs
Name Other name DUSP no. MAPK
specificity
Subcellular
localization
VHR DUSP3 ERK1/2 Nuclear
MKP-6 MKP-L DUSP14 ERK1/2, JNK Cytoplasmic
DUSP18 DUSP18 JNK N/D
DSP-2 JSP1, JKAP, VHX DUSP22 JNK, p38 Cytoplasmic
MKP-8 DUSP26 p38 Nuclear
1234 K. Kondoh, E. Nishida / Biochimica et Biophysica Acta 1773 (2007) 1227–1237co-stimulatory signaling [139]. Besides VHR and MKP-6, there
are several low molecular weight dual-specificity phosphatases
that dephosphorylate MAPKs at least in vitro (see Table 2).
However, function of these phosphatases is unknown.
9. Conclusion and perspectives
Modulation of MAPK activities is crucially important to
regulate many biological processes. As MKPs can depho-
sphorylate MAPKs, it has been thought that MKPs play a
pivotal role in regulation of MAPK activities. Thus, many
studies have uncovered the properties and function of MKPs,
although there are several members of MKPs, such as hVH-3,
MKP-X and MKP-7, whose function is still unclear. Recent
studies employing relevant model systems have revealed non-
redundant roles of each MKP in a variety of biological
processes. Knock-out of MKP-1, MKP-4, MKP-5 and PAC-1
in mice has revealed their function, such as the essential role of
MKP-1, MKP-5, and PAC-1 in immune system. It is of great
interest that three MKPs play different roles in the same system
with their strict substrate specificity. Similarly, the study with
mice lacking the other MKPs will reveal their important roles.
Moreover, as MKPs seem to have redundancy in function,
creating double knockout mice of MKPs will significantly
increase our understanding of the function of MKPs. In chicken
embryos, a variety of techniques, including tissue ablation,
transplantation, RNA interference and viral injection have
revealed the essential role of MKP-3 in limb development.
Thus, the combination of a range of model systems and
techniques will facilitate future studies.
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